OHR Pharmaceutical Inc.

Financials

v3.6.0.2
Consolidated Balance Sheets (Unaudited) - USD ($)
Dec. 31, 2016
Sep. 30, 2016
CURRENT ASSETS    
Cash and cash equivalents $ 13,489,082 $ 12,546,890
Prepaid expenses and other current assets 371,391 738,118
Total Current Assets 13,860,473 13,285,008
EQUIPMENT, net 187,728 198,631
OTHER ASSETS    
Security deposit 12,243 12,243
Intangible assets, net 14,925,520 15,208,219
Goodwill 740,912 740,912
TOTAL ASSETS 29,726,876 29,445,013
CURRENT LIABILITIES    
Accounts payable and accrued expenses 3,886,275 4,394,068
Notes payable 87,798
Total Current Liabilities 3,886,275 4,481,866
TOTAL LIABILITIES 3,886,275 4,481,866
STOCKHOLDERS' EQUITY    
Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par value, 0 shares issued and outstanding, respectively  
Common stock; 180,000,000 shares authorized, $0.0001 par value, 35,961,396 and 32,076,396 shares issued and outstanding, respectively 3,596 3,207
Additional paid-in capital 117,090,270 109,237,551
Accumulated deficit (91,253,265) (84,277,611)
Total Stockholders' Equity 25,840,601 24,963,147
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 29,726,876 $ 29,445,013
v3.6.0.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Dec. 31, 2016
Dec. 31, 2015
OPERATING EXPENSES    
General and administrative $ 1,746,356 $ 1,218,128
Research and development 4,931,144 2,076,280
Depreciation and amortization 298,435 297,740
OPERATING LOSS 6,975,935 3,592,148
OTHER INCOME (EXPENSE)    
Change in fair value of contingent consideration   (2,557,549)
Other income   3,419
Interest income (expense), net 281 816
Total Other Income (Expense) 281 (2,553,314)
LOSS FROM OPERATIONS BEFORE INCOME TAXES (6,975,654) (6,145,462)
NET LOSS $ (6,975,654) $ (6,145,462)
BASIC AND DILUTED LOSS PER SHARE (in dollars per share) $ (.21) $ (.20)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:    
BASIC AND DILUTED (in shares) 32,836,505 30,472,493
v3.6.0.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Dec. 31, 2016
Dec. 31, 2015
OPERATING ACTIVITIES    
Net loss $ (6,975,654) $ (6,145,462)
Adjustments to reconcile net loss to net cash used by operating activities:    
Common stock issued for services 440,052 137,424
Stock option expense 566,573 316,819
Change in fair value of contingent consideration   2,557,549
Depreciation 15,736 15,042
Amortization of intangible assets 282,699 282,698
Changes in operating assets and liabilities    
Prepaid expenses and deposits 247,926 (1,439,033)
Accounts payable and accrued expenses (507,793) 948,522
Net Cash Used in Operating Activities (5,930,461) (3,326,441)
INVESTING ACTIVITIES    
Purchase of property and equipment (4,833) (10,550)
Net Cash Used in Investing Activities (4,833) (10,550)
FINANCING ACTIVITIES    
Proceeds for issuance of common stock for cash, net 6,846,483  
Proceeds from warrants exercised for cash 118,801 13,540
Repayments of short-term notes payable (87,798) (48,063)
Net Cash Provided by/(Used in) Financing Activities 6,877,486 (34,523)
NET CHANGE IN CASH AND CASH EQUIVALENTS 942,192 (3,371,514)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 12,546,890 28,697,323
CASH AND CASH EQUIVALENTS AT END OF PERIOD 13,489,082 25,325,809
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION    
Interest $ 1,320 406
NON CASH FINANCING ACTIVITIES:    
Settlement of contingent consideration   $ 2,061,136